Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4 ...

Marc Dubrick and Grace Alexander claimed hard-fought victories Sunday morning in the 42nd St. Anthony's Triathlon along St.

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Among research news last week, Gilead Sciences released positive new Phase III data on progression fee survival for its Trodelvy plus Keytruda in breast cancer. Roivant company Immunovant last week ...

Phixius by Nacha?a secure, peer-to-peer payment information network?announced today that ValidiFI is live on the Phixius network as an additional provider of bank account validation. Phixius now ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...